Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study
Open-label, no control groupHumansWith polydatin
This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 30 women with endometriosis enrolled. 28 completed.
- Dose used in the study
- 600 mg of ultramicronised palmitoylethanolamide twice a day for 10 days, then 400 mg of palmitoylethanolamide with 40 mg of polydatin twice a day for 80 days
- Duration
- 90 days, with a 30-day follow-up
- What was measured
- Pelvic pain and related symptoms on visual analogue scales, quality of life and psychological wellbeing questionnaires.
What the authors reported
This open-label pilot study found:
- Chronic pelvic pain scores fell from 7.2 to 2.6 (p < 0.0001), with smaller falls in period pain and other symptoms.
- Quality of life and psychological wellbeing scores improved.
- Use of pain medication fell.
- The authors reported no serious side effects.
Limits of this study
A single-group study with no placebo and no blinding. The authors name the small sample, the open-label design and the short treatment period as limits. The authors reported no conflicts of interest. The funding statement was not visible on the page checked.
Source
PubMed 31496832 · doi:10.2147/IJWH.S204275
Entry checked against the abstract on PubMed, and the full text at the publisher (Dove Medical Press) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.